Niemann-Pick disease (NP) refers to a group of inherited metabolic disorders known as lipid storage diseases. Lipids (fatty materials such as waxes, fatty acids, oils, and cholesterol) and proteins are usually broken down into smaller components to provide energy for the body. In Niemann-Pick disease, harmful quantities of lipids accumulate in the spleen, liver, lungs, bone marrow, and the brain. Symptoms may include lack of muscle coordination, brain degeneration, eye paralysis, learning problems, loss of muscle tone, increased sensitivity to touch, spasticity, feeding and swallowing difficulties, slurred speech, and an enlarged liver and spleen. There may be clouding of the cornea and a characteristic cherry-red halo develops around the center of the retina. The disease has 4 related types. Type A, the most severe form, occurs in early infancy. It is characterized by an enlarged liver and spleen, swollen lymph nodes, and profound brain damage by six months of age. Children with this type rarely live beyond 18 months. Type B involves an enlarged liver and spleen, which usually occurs in the pre-teen years. The brain is not affected. In types A and B, insufficient activity of an enzyme called sphingomyelinase causes the build up of toxic amounts of sphingomyelin, a fatty substance present in every cell of the body. Types C and D may appear early in life or develop in the teen or adult years. Affected individuals have only moderate enlargement of the spleen and liver, but brain damage may be extensive and cause an inability to look up and down, difficulty in walking and swallowing, and progressive loss of vision and hearing. Types C and D are characterized by a defect that disrupts the transport of cholesterol between brain cells. Type D usually occurs in people with an ancestral background in Nova Scotia. Types C and D are caused by a lack of the NPC1 or NPC 2 proteins.
There is currently no cure for Niemann-Pick disease. Children usually die from infection or progressive neurological loss.
There is currently no effective treatment for persons with type A. Bone marrow transplantation has been attempted in a few patients with type B, and encouraging results have been reported. The development of enzyme replacement and gene therapies might also be helpful
for those with type B. Individuals with types C and D are frequently placed on a low-cholesterol diet and/or cholesterol lowering drugs, but research has not shown these interventions
to change the abnormal cholesterol metabolism or halt disease progression..
Ara Parseghian Medical Research Foundation
[For Niemann-Pick Type C Disease] 3530 East Campo Abierto Suite 105 Tucson, AZ 85718-3327 victory@parseghian.org http://www.parseghian.org Tel: 520-577-5106 Fax: 520-577-5212 |
National Niemann-Pick Disease Foundation, Inc. P.O. Box 49 401 Madison Avenue, Suite B Ft. Atkinson, WI 53538 nnpdf@nnpdf.org http://www.nnpdf.org Tel: 920-563-0930 877-CURE-NPC (287-3672) Fax: 920-563-0931 |
National Tay-Sachs and Allied Diseases Association 2001 Beacon Street Suite 204 Boston, MA 02135 info@ntsad.org http://www.ntsad.org Tel: 800-90-NTSAD (906-8723) Fax: 617-277-0134 |
Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last updated October 6, 2011